Coherus Oncology (FRA:8C5) Accounts Payable & Accrued Expense : €191.5 Mil (As of Mar. 2025)

View and export this data going back to 2014. Start your Free Trial

What is Coherus Oncology Accounts Payable & Accrued Expense?

Coherus Oncology's quarterly accounts payable & accrued expense declined from Sep. 2024 (€240.4 Mil) to Dec. 2024 (€237.0 Mil) and declined from Dec. 2024 (€237.0 Mil) to Mar. 2025 (€191.5 Mil).

Coherus Oncology's annual accounts payable & accrued expense increased from Dec. 2022 (€105.5 Mil) to Dec. 2023 (€282.5 Mil) but then declined from Dec. 2023 (€282.5 Mil) to Dec. 2024 (€237.0 Mil).

Coherus Oncology Accounts Payable & Accrued Expense Historical Data

The historical data trend for Coherus Oncology's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus Oncology Accounts Payable & Accrued Expense Chart

Coherus Oncology Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

98.87

123.74

105.51

282.53

237.01

Coherus Oncology Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															311.63	404.61	240.39	237.01	191.54

Coherus Oncology Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Coherus Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus Oncology Inc (FRA:8C5) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

CHRS:USA

Address

333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065

Website

https://www.coherus.com

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline which includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer.

Coherus Oncology Headlines

No Headlines